

Adopted as Rule: September 30, 2013

Toxicological Summary for Carbon Tetrachloride:

CAS: 56-23-5

Synonyms: Tetrachloromethane, Carbona, Carbon chloride, Carbon tet, Methane tetrachloride, Perchloromethane, benzinofom, 1,1,1,1-Tetrachloromethane, Benzinofom, Freon 10, Halon 104, Tetraform, Tetrasol

Acute Non-Cancer Health Risk Limit (nHRL_{acute}) = 100 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Acute intake rate, L/kg/d})}$$

$$= \frac{(0.18 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.289 \text{ L/kg-d})}$$

$$= 124 \text{ rounded to } 100 \text{ µg/L}$$

Reference Dose / Concentration: 0.18 mg/kg-d (F344N rats)
 Source of toxicity value: MDH, 2012
 Point of Departure: 25 mg/kg-d (NOAEL), Developmental study (Narotsky, et al., 1997b)
 Human Equivalent Dose Adjustment: 5.3 mg/kg-d [25 x 0.21] (MDH, 2011)
 Total uncertainty factor: 30
 UF allocation: 3 for interspecies variability (toxicodynamics); 10 for intraspecies variability
 Critical effect(s): Increased litter resorptions
 Co-critical effect(s): Regenerative hepatocyte proliferation
 Additivity endpoint(s): Developmental system; Hepatic (liver) system

Short-term Non-Cancer Health Risk Limit (nHRL_{short-term}) = 3 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Short-term intake rate, L/kg/d})}$$

$$= \frac{(0.0037 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.289 \text{ L/kg-d})}$$

$$= 2.6 \text{ rounded to } 3 \text{ µg/L}$$

Reference Dose / Concentration: 0.0037 mg/kg-d (F344N rats)

Source of toxicity value: MDH 2012
 Point of Departure: 5 mg/kg-d (minimal LOAEL), 10-day immunotoxicity gavage study (Smialowicz et al, 1991)
 Human Equivalent Dose Adjustment: 1.1 mg/kg-d [5 x 0.21] (MDH, 2011)
 Total uncertainty factor: 300
 UF allocation: 3 for interspecies variability (toxicodynamics); 10 for intraspecies variability; 3 for database uncertainty – no multi-generation study to adequately assess reproductive effects; 3 for minimal LOAEL to NOAEL extrapolation
 Critical effect(s): Minimal vacuolar degeneration in the liver
 Co-critical effect(s): None
 Additivity endpoint(s): Hepatic (liver) system

Subchronic Non-Cancer Health Risk Limit (nHRL_{subchronic}) = nHRL_{short-term} = 3 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Subchronic intake rate, L/kg/d})}$$

$$= \frac{(0.0098 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.077 \text{ L/kg-d})}$$

$$= \mathbf{25} \text{ rounded to } 30 \text{ µg/L}$$

Reference Dose / Concentration: 0.0098 mg/kg-d (SD rats)
 Source of toxicity value: MDH 2012
 Point of Departure: 3.9 mg/kg-d (BMDL_{adj}); 12-week gavage study (Bruckner, et al., 1986)
 Human Equivalent Dose Adjustment: 0.98 mg/kg-d [3.9 x 0.25] (MDH, 2011)
 Total uncertainty factor: 100
 UF allocation: 3 for interspecies variability (toxicodynamics); 10 for intraspecies variability; 3 for database uncertainty – no multi-generation study to adequately assess reproductive effects
 Critical effect(s): Increased serum liver enzyme levels, liver lesions
 Co-critical effect(s): Increased liver enzyme levels, liver lesions, increased liver weight, alterations of liver histopathology, increased bilirubin, decreased serum glucose, increased spleen and thymus weights
 Additivity endpoint(s): Hepatic (liver) system, Immune system

The Subchronic nHRL must be protective of the short-term exposures that occur within the short-term period and therefore, the Subchronic nHRL is set equal to the Short-term nHRL of 3 µg/L. Additivity Endpoints: Hepatic (liver) system

Chronic Non-Cancer Health Risk Limit (nHRL_{chronic}) = nHRL_{short-term} = 3 µg/L

$$= \frac{(\text{Reference Dose, mg/kg/d}) \times (\text{Relative Source Contribution}) \times (\text{Conversion Factor})}{(\text{Chronic intake rate, L/kg/d})}$$

$$= \frac{(0.0033 \text{ mg/kg/d}) \times (0.2) \times (1000 \text{ µg/mg})}{(0.043 \text{ L/kg-d})}$$

$$= \mathbf{15.3} \text{ rounded to } 20 \text{ µg/L}$$

Reference Dose / Concentration:	0.0033 mg/kg-d (laboratory animal)
Source of toxicity value:	MDH 2012 (same as US EPA 2010)
Point of Departure:	3.9 mg/kg-d (BMDL _{adj}); 12-week gavage study (Bruckner, et al., 1986)
Human Equivalent Dose Adjustment:	0.98 mg/kg-d [3.9 x 0.25] (MDH, 2011)
Total uncertainty factor:	300
UF allocation:	3 for interspecies variability (toxicodynamics); 10 for intraspecies variability; 3 for database uncertainty – no multi-generation study to adequately assess reproductive effects; 3 for extrapolation from subchronic to chronic duration
Critical effect(s):	Increased serum liver enzyme levels, liver lesions
Co-critical effect(s):	Increased liver enzyme levels, liver lesions, increased liver weight, alterations of liver histopathology, increased bilirubin, decreased serum glucose, increased spleen and thymus weights
Additivity endpoint(s):	Hepatic (liver) system, Immune system

The chronic nHRL must be protective of the short-term exposures that occur within the short-term period and therefore, the chronic nHRL is set equal to the short-term nHRL of 3 µg/L.

Additivity Endpoints: Hepatic (liver) system

Cancer Health Risk Limit (cHRL) = 1 µg/L

$$= \frac{(\text{Additional Lifetime Cancer Risk}) \times (\text{Conversion Factor})}{[(\text{SF} \times \text{ADAF}_{<2 \text{ yr}} \times \text{IR}_{<2\text{yr}} \times 2) + (\text{SF} \times \text{ADAF}_{2-<16 \text{ yr}} \times \text{IR}_{2-<16\text{yr}} \times 14) + (\text{SF} \times \text{ADAF}_{16+ \text{ yr}} \times \text{IR}_{16+\text{yr}} \times 54)] / 70}$$

$$= \frac{(1\text{E-}5) \times (1000 \text{ µg/mg})}{[(0.07 \times 10 \times 0.137 \text{ L/kg-d} \times 2) + (0.07 \times 3 \times 0.047 \text{ L/kg-d} \times 14) + (0.07 \times 1 \times 0.039 \text{ L/kg-d} \times 54)] / 70}$$

$$= \mathbf{1.46} \text{ rounded to } \mathbf{1} \text{ µg/L}$$

Cancer classification:	<i>Likely to be carcinogenic to humans</i> (US EPA IRIS 2010)
Slope factor:	0.07 (laboratory animal; 2-year cancer inhalation study (Nagano et al 2007b as cited by US EPA IRIS 2010))
Source of slope factor:	(US EPA IRIS 2010)
Tumor site(s):	Liver, Adrenal Glands

Volatile: Yes (high)

Summary of changes since 1993/1994 HRL promulgation:

A cancer HRL of 3 µg/L was promulgated in 1993. In 2010, a revised cancer Health-Base Value (HBV) of 1 µg/L was derived. This value is 3 times lower than the 1993 cancer HRL (3 µg/L) as the result of: 1) utilizing more recent intake rates which incorporate higher intake rates during early life; 2) application of age-dependent early-life cancer sensitivity adjustment factors; 3) the use of a new slope factor derived by EPA IRIS 2010; and 4) rounding to one significant digit. In 2010, Acute, Short-term, Subchronic and Chronic HBVs of 200, 3, 3, and 3 µg/L were derived. MDH reevaluated the non-cancer HBVs in 2012 to incorporate HED methodology. The resulting Acute HBV (100 µg/L) was 2-fold lower than the 2010 value. The Short-term, Subchronic and Chronic (non-cancer) HBVs (3 µg/L) were unchanged. HBV values derived in 2010 and updated in 2012 were adopted as HRLs in 2013, and the 1993 HRL was repealed.

Summary of toxicity testing for health effects identified in the Health Standards Statute:

	Endocrine	Immunotoxicity	Development	Reproductive	Neurotoxicity
Tested?	Secondary Observations	Yes	Yes	Yes	Yes
Effects?	Yes ¹	Yes ²	Yes ³	Yes ⁴	Yes ⁵

Note: Even if testing for a specific health effect was not conducted for this chemical, information about that effect might be available from studies conducted for other purposes. Most chemicals have been subject to multiple studies in which researchers identify a dose where no effects were observed, and the lowest dose that caused one or more effects. A toxicity value based on the effect observed at the lowest dose across all available studies is considered protective of all other effects that occur at higher doses.

Comments on extent of testing or effects:

¹ In a developmental study in rats, the researchers suggested that the all-or-none nature of the observed full-litter resorptions point to a maternally mediated response and produced evidence that the response is associated with reduced levels of progesterone and luteinizing hormone (LH) in the dams during dosing with carbon tetrachloride. (Narotsky et al., 1997a, 1995 cited in US EPA 2010).

Greim et al. (2009) hypothesized modes of action (MOA) for the induction of mouse pheochromocytomas that included endocrine disturbance, impairment of mitochondrial function, uncoupling of oxidative phosphorylation, hepatotoxicity, and nephrotoxicity leading to impaired calcium homeostasis, but provided no support for any of these hypothesized MOAs.(cited in US EPA 2010)

²Results of available studies indicate that carbon tetrachloride produces adverse effects on T-cell-dependent immunity at administered doses (beginning at 50 mg/kg-day) that are hepatotoxic. However, it is important to note that immunological effects were, at least in part, secondary to hepatotoxicity and the process of hepatic repair.

^{3,4}The critical study selected for the acute HRL is a developmental study that reported increased litter resorptions beginning at a Human Equivalent Dose of 10.5 mg/kg-day. No adequate oral reproductive toxicity studies were conducted for carbon tetrachloride. Developmental effects (decreased fetal body weight and delayed ossification) and reproductive effects (testicular atrophy, testicular degeneration, and reduced fertility) were reported in inhalation studies at doses higher than those that produced liver and kidney toxicity.

⁵No oral animal toxicity studies reported neurotoxicity following exposure to carbon tetrachloride. Human reports of exposure to high doses of carbon tetrachloride by inhalation or ingestion mentioned headaches, drowsiness, comas, or seizures. In acute inhalation studies, animals exposed to high doses (4600-1200 ppm) of carbon tetrachloride experienced stupor, incoordination, and unconsciousness.

References:

- Agency for Toxic Substances and Disease Registry. (2005). Toxicological Profile for Carbon Tetrachloride. from <http://www.atsdr.cdc.gov/toxprofiles/tp30.pdf>
- Agency for Toxic Substances and Disease Registry (ATSDR) - MRLs. (2009). Minimal Risk Levels for Hazardous Substances (MRLs). from http://www.atsdr.cdc.gov/mrls/mrls_list.html
- Agency for Toxic Substances and Disease Registry (ATSDR) - Toxicological Profiles. Toxicological Profile Information Sheet. from <http://www.atsdr.cdc.gov/toxpro2.html>
- Ahn, Y. K., & Kim, J. H. (1993). Preventive effects of diphenyl dimethyl dicarboxylate on the immunotoxicity of carbon tetrachloride in ICR mice. *J Toxicol Sci*, 18(3), 185-195.
- Allis, J. W., Ward, T. R., Seely, J. C., & Simmons, J. E. (1990). Assessment of hepatic indicators of subchronic carbon tetrachloride injury and recovery in rats. *Fundam Appl Toxicol*, 15(3), 558-570.
- Alumot, E., Nachtom, E., Mandel, E., & Holstein, P. (1976). Tolerance and acceptable daily intake of chlorinated fumigants in the rat diet. *Food Cosmet Toxicol*, 14(2), 105-110.
- Bruckner, J. V., MacKenzie, W. F., Muralidhara, S., Luthra, R., Kyle, G. M., & Acosta, D. (1986). Oral toxicity of carbon tetrachloride: acute, subacute, and subchronic studies in rats. *Fundam Appl Toxicol*, 6(1), 16-34.
- California Environmental Protection Agency-OEHHA Toxicity Criteria Database. from <http://www.oehha.ca.gov/risk/ChemicalDB/index.asp>
- California Environmental Protection Agency - OEHHA Cancer Potency Values. (2005). OEHHA Toxicity Criteria Database. from <http://www.oehha.ca.gov/risk/pdf/cancerpotalpha81005.pdf>
- California Water Resources Control Board. (2008). Water Quality Limits for Constituents and Parameters. from http://www.waterboards.ca.gov/water_issues/programs/water_quality_goals/docs/limit_tables_2008.pdf
- Condie, L. W., Dana Laurie, R., Mills, T., Robinson, M., & Peter Bercz, J. (1986). Effect of gavage vehicle on hepatotoxicity of carbon tetrachloride in CD-1 mice: Corn oil versus tween-60 aqueous emulsion. [doi: DOI: 10.1016/0272-0590(86)90148-X]. *Fundamental and Applied Toxicology*, 7(2), 199-206.
- Eschenbrenner, A., & Miller, E. (1946). Liver necrosis and the induction of carbon tetrachloride hepatomas in strain A mice. *Journal of the National Cancer Institute*.
- Guo, T. L., McCay, J. A., Brown, R. D., Musgrove, D. L., Germolec, D. R., Butterworth, L., et al. (2000). Carbon tetrachloride is immunosuppressive and decreases host resistance to *Listeria*

monocytogenes and *Streptococcus pneumoniae* in female B6C3F1 mice. *Toxicology*, 154(1-3), 85-101.

Hayes, J. R., Condie, L. M., Jr., & Borzelleca, J. F. (1986). Acute, 14-day repeated dosing, and 90-day subchronic toxicity studies of carbon tetrachloride in CD-1 mice. *Fundam Appl Toxicol*, 7(3), 454-463.

Health Canada - Priority Substances Assessment Program and Screening Assessment Reports. from <http://www.hc-sc.gc.ca/ewh-semt/pubs/contaminants/index-eng.php#existsub>

International Agency for Research on Cancer (IARC). Complete List of Agents evaluated and their classification. from <http://monographs.iarc.fr/ENG/Classification/index.php>

Kaminski, N. E., Barnes, D. W., Jordan, S. D., & Holsapple, M. P. (1990). The role of metabolism in carbon tetrachloride-mediated immunosuppression: in vivo studies. *Toxicol Appl Pharmacol*, 102(1), 9-20.

Kaminski, N. E., Jordan, S. D., & Holsapple, M. P. (1989). Suppression of humoral and cell-mediated immune responses by carbon tetrachloride. *Fundam Appl Toxicol*, 12(1), 117-128.

Koporec, K. P., Kim, H. J., Mackenzie, W. F., & Bruckner, J. V. (1995). Effect of oral dosing vehicles on the subchronic hepatotoxicity of carbon tetrachloride in the rat. *Journal of Toxicology and Environmental Health*, 44(1), 13 - 27.

Ladics, G. S., Smith, C., Elliott, G. S., Slone, T. W., & Loveless, S. E. (1998). Further evaluation of the incorporation of an immunotoxicological functional assay for assessing humoral immunity for hazard identification purposes in rats in a standard toxicology study. *Toxicology*, 126(2), 137-152.

Lee, V. M., Cameron, R. G., & Archer, M. C. (1998). Zonal location of compensatory hepatocyte proliferation following chemically induced hepatotoxicity in rats and humans. *Toxicol Pathol*, 26(5), 621-627.

Litchfield, M. H., & Gartland, C. J. (1974). Plasma enzyme activity and hepatocellular changes in the beagle dog after single or repeated administration of carbon tetrachloride. [doi: DOI: 10.1016/0041-008X(74)90253-1]. *Toxicology and Applied Pharmacology*, 30(1), 117-128.

Minnesota Department of Health (MDH). (2011). MDH Health Risk Assessment Methods to Incorporate Human Equivalent Dose Calculations into Derivation of Oral Reference Doses. from <http://www.health.state.mn.us/divs/eh/risk/guidance/hedrefguide.pdf>

Narotsky, M. G., Brownie, C. F., & Kavlock, R. J. (1997a). Critical period of carbon tetrachloride-induced pregnancy loss in Fischer-344 rats, with insights into the detection of resorption sites by ammonium sulfide staining. *Teratology*, 56(4), 252-261.

Narotsky, M. G., & Kavlock, R. J. (1995). A multidisciplinary approach to toxicological screening: II. Developmental toxicity. *J Toxicol Environ Health*, 45(2), 145-171.

Narotsky, M. G., Pegram, R. A., & Kavlock, R. J. (1997b). Effect of dosing vehicle on the developmental toxicity of bromodichloromethane and carbon tetrachloride in rats. *Fundam Appl Toxicol*, 40(1), 30-36.

- National Toxicology Program (NTP). from <http://ntp.niehs.nih.gov/?objectid=25BC6AF8-BDB7-CEBA-F18554656CC4FCD9>
- Smialowicz, R. J., Simmons, J. E., Luebke, R. W., & Allis, J. W. (1991). Immunotoxicologic assessment of subacute exposure of rats to carbon tetrachloride with comparison to hepatotoxicity and nephrotoxicity. *Fundam Appl Toxicol*, 17(1), 186-196.
- Steup, D. R., Hall, P., McMillan, D. A., & Sipes, I. G. (1993). Time course of hepatic injury and recovery following coadministration of carbon tetrachloride and trichloroethylene in Fischer-344 rats. *Toxicol Pathol*, 21(3), 327-334.
- Syracuse Research PhysProp Database. from <http://www.syrres.com/what-we-do/databaseforms.aspx?id=386>
- The International Programme on Chemical Safety. Chemicals Assessment. from <http://www.who.int/ipcs/assessment/en/>
- Toxicology Excellence for Risk Assessment - ITER International Toxicity Estimates for Risk (ITER). from http://iter.ctcnet.net/publicurl/pub_search_list.cfm
- TOXNET. Toxicology Data Network Search. from <http://toxnet.nlm.nih.gov/>
- U.S. Environmental Protection Agency - Health Effects Assessment Summary Table (HEAST). (July 1997).
- U.S. Environmental Protection Agency - IRIS. Integrated Risk Information Systems (IRIS) A-Z List of Substances. from <http://cfpub.epa.gov/ncea/iris/index.cfm?fuseaction=iris.showSubstanceList>
- U.S. Environmental Protection Agency - IRIS Summary. (2010). Carbon Tetrachloride IRIS Summary. from <http://www.epa.gov/iris/subst/0020.htm>
- U.S. Environmental Protection Agency - National Center for Environmental Assessment. from http://cfpub.epa.gov/ncea/cfm/archive_whatsnew.cfm
- U.S. Environmental Protection Agency - Office of Drinking Water. (2011). 2011 Edition of the Drinking Water Standards and Health Advisories. from http://water.epa.gov/action/advisories/drinking/drinking_index.cfm#dw-standards
- U.S. Environmental Protection Agency - Office of Pesticide Programs Reregistration Status. Pesticide Registration Status. from <http://www.epa.gov/pesticides/reregistration/status.htm>
- U.S. Environmental Protection Agency - Office of Research and Development. (1988). Recommendations for and Documentation of Biological Values for Use in Risk Assessment. from <http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855>
- U.S. Environmental Protection Agency - Office of the Science Advisor. (2011). Recommended Use of Body Weight^{3/4} as the Default Method in Derivation of the Oral Reference Dose. from <http://www.epa.gov/raf/publications/pdfs/recommended-use-of-bw34.pdf>

- U.S. Environmental Protection Agency - Regional Screening Tables. Mid-Atlantic Risk Assessment - Regional Screening Table. from http://www.epa.gov/reg3hwmd/risk/human/rb-concentration_table/Generic_Tables/index.htm
- U.S. Environmental Protection Agency - Toxicity and Exposure Assessment for Children's Health (TEACH). from <http://www.epa.gov/teach/>
- U.S. Environmental Protection Agency - Voluntary Children's Chemical Evaluation Program (VCCEP). VCCEP Chemicals. from <http://www.epa.gov/oppt/vccep/pubs/chemmain.html>
- U.S. Environmental Protection Agency - Toxicological Review. (2010). Toxicological Review of Carbon Tetrachloride. from <http://www.epa.gov/ncea/iris/toxreviews/0020tr.pdf>
- U.S. Geological Survey - Health-Based Screening Levels. from <http://infotrek.er.usgs.gov/apex/f?p=HBSL:HOME:0>
- Wang, P. Y., Kaneko, T., Tsukada, H., Nakano, M., Nakajima, T., & Sato, A. (1997). Time courses of hepatic injuries induced by chloroform and by carbon tetrachloride: comparison of biochemical and histopathological changes. *Arch Toxicol*, 71(10), 638-645.
- Weisburger, E. K. (1977). Carcinogenicity studies on halogenated hydrocarbons. *Environ Health Perspect*, 21, 7-16.
- World Health Organization - Guidelines for Drinking-Water Quality. (2008). from http://www.who.int/water_sanitation_health/dwg/gdwq3rev/en/index.html